
JUNS
Healthcare · Biotechnology · $2.3M market cap
$1.76-0.10 (-5.4%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | Time not confirmed | — | — | — |
| Aug 14, 2026 | Time not confirmed | — | -5.06 | — |
| Jun 3, 2026 | Time not confirmed | — | -4.39 | — |
| Feb 25, 2026 | Time not confirmed | -0.06 | -0.07 | -24.7% |
| Nov 14, 2025 | After the close | -0.08 | -0.07 | +12.5% |
| Aug 18, 2025 | Time not confirmed | -0.07 | -0.07 | 0.0% |
| May 15, 2025 | After the close | -0.03 | -0.05 | -66.7% |
| Feb 26, 2025 | Time not confirmed | -0.02 | -0.05 | -150.0% |
| Dec 23, 2024 | After the close | -0.02 | -0.02 | 0.0% |
| Jan 5, 2022 | Time not confirmed | — | -0.07 | — |
| Nov 9, 2021 | Time not confirmed | — | -0.03 | — |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the…